ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 161 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2018. The put-call ratio across all filers is 0.99 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $902,000 | +136.7% | 24,600 | +200.0% | 0.04% | +104.5% |
| Q2 2019 | $381,000 | -86.0% | 8,200 | -87.9% | 0.02% | -86.5% |
| Q1 2019 | $2,716,000 | +17.1% | 67,643 | +34.1% | 0.16% | +9.4% |
| Q4 2018 | $2,320,000 | +478.6% | 50,443 | +457.8% | 0.15% | +727.8% |
| Q3 2018 | $401,000 | -88.9% | 9,043 | -82.0% | 0.02% | -87.7% |
| Q1 2018 | $3,626,000 | +136.8% | 50,143 | +64.1% | 0.15% | +87.2% |
| Q3 2017 | $1,531,000 | -40.3% | 30,560 | -44.9% | 0.08% | -42.6% |
| Q2 2017 | $2,566,000 | +1001.3% | 55,460 | +134.5% | 0.14% | +1033.3% |
| Q2 2016 | $233,000 | -93.1% | 23,650 | -88.2% | 0.01% | -92.1% |
| Q1 2016 | $3,396,000 | +47.1% | 200,858 | +93.6% | 0.15% | +39.4% |
| Q4 2015 | $2,309,000 | +187.9% | 103,746 | +204.8% | 0.11% | +263.3% |
| Q3 2015 | $802,000 | -80.2% | 34,033 | -22.1% | 0.03% | -78.6% |
| Q1 2015 | $4,046,000 | +190.7% | 43,696 | +26.9% | 0.14% | +169.2% |
| Q4 2014 | $1,392,000 | – | 34,441 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $22,344,000 | 10.09% |
| Altium Capital Management LP | 2,515,785 | $12,579,000 | 3.47% |
| Deep Track Capital, LP | 5,641,668 | $28,208,000 | 1.99% |
| Paradigm Biocapital Advisors LP | 839,257 | $4,196,000 | 1.20% |
| SABBY MANAGEMENT, LLC | 940,400 | $4,702,000 | 0.68% |
| Monaco Asset Management SAM | 500,000 | $2,500,000 | 0.62% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 5,000,000 | $25,000,000 | 0.52% |
| CVI Holdings, LLC | 1,460,595 | $7,303,000 | 0.48% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $13,566,000 | 0.38% |
| Rhenman & Partners Asset Management AB | 1,000,000 | $4,960,000 | 0.33% |